AstraZeneca Restarts MEK Inhibitor In Singapore Research Pact
This article was originally published in PharmAsia News
Executive Summary
With two compounds already identified for screening - including one that fizzled in Phase II for melanoma - AstraZeneca kicked off a partnership with a pair of Singapore institutions to come up with drugs for liver cancer, a disease especially prevalent in East Asia, which accounts for 75 percent of the world's patients
You may also be interested in...
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 2 of 2)
AstraZeneca's Head of R&D in Asia Patrick Keohane sat down recently with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.